ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CGON vs CRSP // GROSS PROFIT MARGIN

CG Oncology Inc. (NASDAQ) VS. CRISPR Therapeutics AG (NASDAQ) • 15-METRIC TALLY: CGON 9 — CRSP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CGON VS. CRSP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CGON CRSP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -20.80% -30.60% +9.80 CGON /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -2.35% -6.59% +4.24 CGON /fcf-yield <GO>
Operating Margin -12.10% -60.00% +47.90 CGON /operating-margins <GO>
Net Profit Margin -10.20% -60.00% +49.80 CGON /net-margins <GO>
Revenue Growth (YoY) 8.80% -65.00% +73.80 CGON /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 7.97 +18.03 CGON /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 CGON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 54.9 -9.60 CRSP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.07 1.12 -0.05 CRSP /macro-sensitivity <GO>
Forward P/E Multiple 20.0x 28.0x -8.00 CGON /forward-pe <GO>
Enterprise Scale & Market Cap $5.63B $5.25B $379.5M CGON /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CGON REV CRSP REV CGON GROSS % CRSP GROSS % CGON FCF CRSP FCF
FY 2025 $0 $3.5M — — -$132.5M -$345.9M
FY 2024 $0 $37.3M — — -$78.9M -$144.7M
FY 2023 $0 $371.2M — — -$45.7M -$277.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CGON // BETA 1.07
CRSP // BETA 1.12